CINRYZE
Commercial- Indications
- Hereditary angioedema
Company intelligence / Profile preview
ViroPharma was a commercial-stage biopharmaceutical company specializing in rare diseases. Its lead product, Cinryze—a C1 esterase inhibitor for hereditary angioedema—was approved and generating significant revenue at the time of its acquisition. The company also marketed Vancocin for severe bacterial infections[5][8]. Clinical results for Cinryze demonstrated significant reduction in severity, duration, and frequency of HAE attacks[5].
5 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ViroPharma Incorporated.